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Abstract
gp350, the major envelope protein of Epstein-Barr-Virus, confers B-cell tropism to the virus by interacting with the B lineage
marker CD21. Here we utilize gp350 to generate tailored exosomes with an identical tropism. These exosomes can be used
for the targeted co-transfer of functional proteins to normal and malignant human B cells. We demonstrate here the co-
transfer of functional CD154 protein on tailored gp350+ exosomes to malignant B blasts from patients with B chronic
lymphocytic leukemia (B-CLL), rendering B blasts immunogenic to tumor-reactive autologous T cells. Intriguingly,
engulfment of gp350+ exosomes by B-CLL cells and presentation of gp350-derived peptides also re-stimulated EBV-specific
T cells and redirected the strong antiviral cellular immune response in patients to leukemic B cells. In essence, we show that
gp350 alone confers B-cell tropism to exosomes and that these exosomes can be further engineered to simultaneously
trigger virus- and tumor-specific immune responses. The simultaneous exploitation of gp350 as a tropism molecule for
tailored exosomes and as a neo-antigen in malignant B cells provides a novel attractive strategy for immunotherapy of B-
CLL and other B-cell malignancies.
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Introduction
Epstein-Barr virus (EBV) is an almost ubiquitous human gamma
herpes virus that infects resting human B-lymphocytes, including
B-CLL cells, with high efficacy [1,2]. EBV’s B-cell tropism is
mainly due to gp350, the viral envelope glycoprotein that interacts
with the cellular complement receptor 2 (CR2, CD21) [3] on B
cells. In EBV seropositive individuals, gp350 mainly elicits CD4+
T-cell responses [4].
Exosomes are endosome-derived membrane vesicles, which are
released by cells of diverse origin including dendritic cells, cancer
cells [5] and EBV-infected B cells [6]. Exosomes bud from
endosomal membranes and accumulate in multivesicular bodies,
which eventually fuse with the cellular membrane and release the
contained vesicles. Exosomes are rich in lipids and membrane
proteins like MHC molecules, TNF-R and tetraspanins [5] but
their specific composition depends on the cell of origin. Exosomes
either fuse to the recipient cell membrane or are engulfed by
phagocytic cells in such a way that exosome proteins are degraded
and loaded onto MHC class II molecules [7]. Obviously, exosomes
can deliver proteins as cargo in a very immunogenic manner so
that they efficiently reactivate specific CD4+ T cell clones [8].
Hence, exosomes can induce strong and epitope-specific immune
responses [9,10] and can be used as an alternative to transfer
strategies using gene vectors and as promising vaccines [11,12].
Chronic lymphocytic leukemia of B-cell origin (B-CLL) is the
most common adult leukemia in the Western hemisphere. B-CLL
is considered as a prototypic disease undergoing immune evasion
as the malignant cells lack important accessory and co-stimulatory
molecules. Thus, despite their expression of high levels of surface
MHC class I and II molecules, which presumably present tumor-
associated antigenic epitopes, the leukemic cells tend to induce
tumor-specific T-cell anergy. Typically, activated T cells from
patients show a significantly reduced expression of CD40 ligand
(CD154) or are completely CD154-negative [13]. As a conse-
quence, T cells from B-CLL patients cannot activate cells through
the CD40 receptor. This interaction, however, is essential for
CD40 signaling and subsequent induction of other immune
accessory molecules like CD80 and CD86, which increase the
antigen-presenting capacity of normal and B-CLL cells. On the
other hand, the EBV-specific cellular immunity is relatively intact
in these patients [2]. To overcome the dysfunction of potentially
tumor-reactive T cells from patients with B-CLL, several
approaches have been developed relying on the stimulation of
B-CLL cells through the CD40 pathway, including the ectopic
expression of CD154 on the leukemic cells, and aiming at the self-
stimulation of these cells [14–17]. In summary, immunotherapy of
B-CLL is promising and CD154 is a potential candidate molecule
to improve the patients’ immune status and, eventually, the clinical
outcome.
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[2] therefore prompted us to investigate the potential of tailored
exosomes to redirect this immunity to malignant B cells. We
present a novel approach for the targeted transfer of functional
cellular proteins to B cells via tailored gp350+ exosomes. In this
approach, gp350 has a dual function: (i) it confers B-cell tropism to
exosomes so that they specifically co-transfer proteins of interest
and (ii) it is a viral neo-antigen for these cells so that they efficiently
reactive gp350-specific T cells. As a proof of concept, we show that
tailored gp350+ exosomes can co-transfer functional CD154 as
immune accessory molecule to B-CLL cells, which are subse-
quently stimulated to express surface molecules like CD54, CD80,
CD86 and CD95 and stimulate autologous tumor- and EBV-
specific T cells.
Results
EBV gp350 is packaged into exosomes, confers B-cell
tropism, and reactivates specific T cells
EBV has a profound B-cell tropism that is mainly conveyed by
gp350, which is the major EBV glycoprotein in the viral envelope
and the ligand for cellular CD21 (CR2) on B cells. We knew from
previous work that exosomes can transport ectopically expressed
proteins such as green fluorescent protein (GFP), which is presumably
present as a cargo in the exosomal lumen. In addition, several
groups provided evidence that surface proteins are incorporated in
exosome membranes [5]. We therefore asked whether gp350
could also become an integral part of exosomes and confer B-cell
tropism to these vesicles. To answer this question, we co-
transfected 293 cells with expression plasmids encoding BLLF1,
the gene of gp350, and gfp. Three days later, we isolated vesicles
from the supernatants of transfected HEK293 cells as described in
Material and Methods and analyzed them by immunoblots for the
presence of gp350 and exosome markers. Gp350 was detected in
vesicles that floated at a density between 1.03 and 1.08 into an
OptiPrep
TM gradient, corresponding to a density between 1.13 to
1.18 in a sucrose gradient and thus in the density described for
exosomes. The gradient also revealed the co-sedimentation of
gp350 with the exosome markers hps70, tsg101 and CD63,
indicating the nature of the gp350+ vesicles as exosomes
(Figure 1A). Flow cytometry of exosomes coupled to latex beads
revealed that gp350 is presumably located within the exosome
membrane because it could be targeted with a specific antibody
(Figure 1B). To demonstrate that gp350 confers B-cell tropism also
to exosomes, we incubated gp350+/gfp+ exosomes with PBMCs
from a healthy donor for one day and then quantified exosome
binding by measuring GFP fluorescence by flow cytometry. This
assay revealed that gp350+/gfp+ exosomes had an EBV-like
tropism because they bound to CD19+ B cells but not to CD19-
negative cells (Figure 1C).
Phagocytic cells engulf exosomes, process their proteins in
lysosomes and present epitops in association with MHC class II
molecules to CD4+ T cells [10]. To further utilize the potential of
gp350+ exosomes to specifically transfer exogenous proteins to B
cells, which, in turn, may activate specific T cells, we generated
exosomes that carried BNRF1, the major tegument protein of
EBV, either alone (BNRF1+) or together with gp350 (BNRF1+/
gp350+). We then incubated purified CD19+ B cells with these
exosomes overnight and used these PBMC as stimulators for an
autologous BNRF1-specific CD4+ T-cell clone. As shown in
Figure 1D, B cells incubated with BNRF1+/gp350+ exosomes
activated the T-cell clone in a concentration-dependent manner
whereas B cells incubated with BNRF1+ exosomes did not activate
the T-cell clone. This result demonstrates the potential of gp350+
exosomes to transfer immunogenic foreign proteins to B cells that
then can activate specific CD4+ T lymphocytes.
Exosomes transfer functional CD154 to B-CLL cells
In a next series of experiments we wanted to elucidate whether
293/gp350+ exosomes can co-transfer functional membrane
proteins to B cells. As a model system but also as a potential
practical application, we chose B-CLL cells that express CD21 and
become immunogenic upon ectopic expression of CD154 on
malignant cells. We, therefore, transfected 293 cells with
expression plasmids for gp350 and CD154 and isolated exosomes
as described above. Again, an immunoblot with a CD154-specific
antibody demonstrated the presence of CD154 in exosome
preparations and an OptiPrep
TM gradient revealed co-sedimen-
tation with gp350 (Figure 1A) indicating the presence of both
proteins on exosomes (Figure 2A). In addition, flow cytometry
revealed that gp350+/CD154+ exosomes specifically bound to
CD19+ B cells from a B-CLL patient (Figure 2B).
To answer the question whether CD154 in gp350+/CD154+
exosomes was functional, HEK293 cells were transfected with a
CD154 expression plasmid either alone or in combination with a
gp350 expression plasmid. Transfer of exosomes to B-CLL cells
was measured with an anti-CD154 antibody by flow cytometry. As
shown in Figure 2C, exosomes that carry both proteins efficiently
conveyed CD154 surface expression to B-CLL cells. CD154+/
gp350– exosomes were only transferred very inefficiently to B-
CLL cells, probably due to an only weak interaction of CD154
with its receptor CD40 on the cell surface. In order to investigate
the immune accessory function of CD154, we loaded B-CLL cells
from an HLA II DR13+ donor either with 293 exosomes, with
exosomes from 293 cells transfected with an expression plasmid for
gp350 (gp350+ exo) or transfected with expression plasmids for
gp350 and CD154 (CD154+/gp350+ exo). One day later, we
added HLA-DR13-restricted gp350-specific CD4+ T cells and
measured their activation with an IFN-c ELISA. This assay
demonstrated the relevance of CD154 for T-cell recognition
because B-CLL cells loaded with CD154+/gp350+ exosomes were
significantly better stimulators than B-CLL cells loaded with
gp350+ exosomes (Figure 2D). Induction of the accessory molecule
ICAM-1 (CD54), the co-stimulatory molecules B7.1 (CD80) and
B7.2 (CD86), and the death receptor Apo1 (CD95) on B-CLL cells
upon incubation with CD154+/gp350+ exosomes (Figure 2E) but
not with exosomes from 293 cells provided an explanation for
improved recognition by T lymphocytes.
gp350 is a neo-antigen in B-CLL cells and activates
specific CD4+ cytolytic T lymphocytes
We knew from previous experiments that PBMCs from healthy
donors, which were incubated with gp350+ exosomes, efficiently
re-stimulated an autologous gp350-specific CD4+ T-cell clone
(data not shown). These experiments implicated that gp350,
which is equally transferred to B-CLL cells by CD154+/gp350+
exosomes, can act as a neo-antigen in B-CLL cells, which are
normally not infected with EBV [18]. This is a very interesting
aspect because B-CLL patients usually maintain a robust and
easily recruited CMV- [19] and EBV-specific T-cell response [2]
although their T cells in general are functionally impaired. For
instance, B-CLL cells infected with EBV or loaded with CMV-
peptides are efficiently killed by autologous T lymphocytes from
B-CLL patients [18,20]. We thus aimed at investigating whether
gp350 serves as a viral neo-antigen in exosome-treated leukemic
cells and whether these cells become targets for gp350-specific
autologous T lymphocytes. We stimulated PBMCs from B-CLL
patients three times with CD154+/gp350+ exosomes as described
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the activated T cells. To this end, we incubated autologous
PBMCs for 24 hours with either CD154+/gp350+ exosomes,
CD154+/gp350– exosomes or unmodified 293 exosomes or left
them untreated. The next day, these cells were labeled with
calcein and used as targets for autologous effector T cells. As
shown in Figure 3, T cells generated by stimulation with gp350+/
CD154+ exosomes efficiently killed autologous PBMCs that
had been activated with CD154+/gp350– or CD154+/gp350+
exosomes as quantified by the release of calcein. Of interest, we
did not observe notable activation of T cells against 293 proteins
as PBMCs incubated with exosomes from non-transfected 293
cells were lysed to almost the same extent as non-activated
autologous PBMCs.
These experiments also demonstrated that PBMCs loaded with
CD154+/gp350+ exosomes were constantly better lysed than
PBMCs loaded with CD154+/gp350– exosomes. This prompted
us to investigate whether T cells specific for gp350 accounted for
this improved lysis. Therefore, we tested the cytolytic activity of
these T cells against EBV-infected lymphoblastoid cells (LCLs),
which are known to be targets for gp350-specific T cells [21], and
against EBV-negative B blasts [22] from an HLA-DR13+ matched
healthy donor. We found that the T cells efficiently lysed allogenic
LCLs, whereas they completely ignored EBV-free B blasts,
indicating the presence of EBV-specific T cells in the effector
population (Figure 3). These data corroborate that the stimulation
of PBMCs with CD154+/gp350+ carrying exosomes is an efficient
method for the activation of B-CLL cells and the reactivation and
Figure 1. gp350 is incorporated into 293 exosomes and confers B cell tropism. (A) 293 cells were transfected with a gp350 expression
plasmid, vesicles in the supernatant were purified as described and fractions of the OptiPrep
TM gradients were spotted onto PVDF membrane.
Immunoblots demonstrated that vesicles carry gp350 and that these vesicles co-sediment with vesicle that carry the exosome markers hsp70, tsg101,
CD63 and ganglioside (GM)1 (www.exocarta.org). Calnexin is present in cell lysates (CL), its absence from exosomes demonstrated the purity of the
preparation. (B) Latex beads were coated with gp350+ exosomes and stained with a gp350-specific antibody. gp350 is accessible and thus probably
located in the exosome membrane (isotype control is shown as grey tinted histogram). (C) gp350 confers B-cell tropism to exosomes. PBMCs from a
healthy donor were incubated for 18 h with gp350+/gfp+ exosomes and then analyzed for GFP fluorescence by flow cytometry. Only CD19+ B-cells
stained positive, whereas an interaction of gp350+ exosomes with CD3+ T cells and CD19– cells (T and NK cells, monocytes) could not be observed.
(D) B cells from a healthy donor were incubated with serial dilutions of exosomes from 293 cells transfected either with a BNRF1 expression plasmid
or co-transfected with expression plasmids for BNRF1 (293/BNRF1) and gp350 (293/BNRF1+/gp350+) for one day. Then, autologous BNRF1-specific
CD4+ T cells were added and their activation was measured with an IFN-c ELISA one day later. T cells were activated at detectable levels by cells
incubated with 293/BNRF1+/gp350+ exosomes but not with 293/BNRF1+ exosomes, indicating the relevance of gp350+ as a mediator of B cell
tropism. An autologous EBV-infected lymphoblastoid cell line (LCL) was enclosed as a positive control.
doi:10.1371/journal.pone.0025294.g001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e25294Figure 2. CD154 is packaged into exosomes as a functional protein and gp350 enhances the transfer of CD154 to B-CLL cells. (A) 293
cells were transiently transfected with an expression plasmid encoding CD154. An immunoblot with a CD154-specific antibody revealed that CD154 is
highly expressed in transfected cell and that the protein is incorporated into exosomes. Shown are immunoblots of cell lysates (CL) and lysates from
purified exosomes (EL) of normal and transfected 293 cells, incubated with CD154- (upper panel) and tsg101-specific antibodies (middle panel). An
OptiPrep
TM gradient revealed co-sedimentation of CD154- and gp350-carrying vesicles (see Figure 1A). (B) Exosomes carrying gp350+ specifically
bind to CD19+ B cells from a B-CLL patient. Fresh B-CLL cells were incubated with purified exosomes from 293 cells transfected with a gp350
expression plasmid and binding of exosomes was measured by flow cytometry. (C) Exosomes carrying CD154 bind only weakly to B-CLL cells,
probably through interaction with CD40, which is highly expressed on these cells. Binding of CD154-carrying exosomes is drastically enhanced by the
co-expression of gp350. 293 cells were co-transfected with expression plasmids for CD154 and/or gp350. Fresh B-CLL cells were co-cultivated with
CD154+/gp350– and CD154+/gp350+ exosomes for two days and binding of exosomes and thus transfer of CD154 was measured by flow cytometry.
Filled histogram = CLL cells with exosomes from untransfected 293 cells. (D) Fresh HLA-DR13+ B-CLL cells were incubated with the exosomes
indicated for one day and then co-incubated for another day with HLA-DR13-restriced gp350-specific CD4+ T cells. The transfer of functional CD154
renders B-CLL cells significantly more immunogenic (E) Incubation of B-CLL cells with CD154+/gp350+ exosomes for two days led to the induction of
immune accessory molecules CD54, CD80, CD86 and CD95. One representative experiment of at least ten is shown.
doi:10.1371/journal.pone.0025294.g002
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patients.
B-CLL cells treated with CD154+/gp350+ exosomes are
potent stimulators of tumor-specific autologous T cells
Having demonstrated that B-CLL cells activated by CD154+/
gp350+ exosomes achieve an activated phenotype, we next wanted
to assess whether these B-CLL cells became immunogenic to
autologous EBV- and CLL-specific T cells. Given the expected
low number of these T cells in peripheral blood, we stimulated
1,5610
7 PBMCs from patients with B-CLL three times within 21
days with lethally irradiated autologous PBMCs that were
incubated with different exosomes as described above. One typical
experiment is shown in Figure 4: before the first stimulation on day
0, PBMCs of this patient consisted mainly of malignant B cells
with only 4% CD3+ T cells. After the third round of stimulation,
cultures incubated with gp350+/CD154+ exosomes almost
exclusively contained CD4+ and CD8+ T-cells (Figure 4A). In
total, stimulation with CD154+/gp350+ exosomes yielded ap-
proximately 1610
7 vital cells on day 31, meaning that the CD4+
and CD8+ T cell counts had increased about 25-fold and 15-fold,
respectively (Figure 4B), while the total cell number slightly
decreased (Figure 4C). In contrast, no viable cells were detectable
in those cultures that were treated with CD154–/gp350–
exosomes derived from non-transfected 293 cells, or that were
left untreated. Thus, stimulation of T cells with B-CLL cells loaded
with CD154+/gp350+ exosomes is a powe rful option to
selectively expand specific T cells from B-CLL patients in vitro.
Next we wanted to elucidate the specificities and cytolytic
activity of these T cells in more detail. As mentioned above, re-
stimulated T cells form B-CLL patients efficiently lysed autologous
PBMCs that were activated with CD154+/gp350– exosomes.
These exosomes do not contain gp350 and, therefore, the T cells
must have recognized cellular antigens. To test whether T cells
specific for B-CLL-associated antigens had been reactivated, we
incubated them with irradiated EBV-negative B-blasts [22] from
an HLA-A2-matched donor as a negative control or B-blasts
loaded with HLA-A2 restricted peptides derived from B-CLL-
associated antigens, namely MDM [23], ETV5 [24] and PU.1
[25]. As shown in Figure 4D, peptide-loaded B-blasts were
efficiently lysed by the T cells stimulated with CD154+/gp350+
exosomes whereas B blasts not loaded with peptides were
completely ignored. Lysis of target cells was efficiently reduced
upon addition of an MHC class I-specific antibody, W6/32,
demonstrating the antigen specificity of the effector T cells.
Discussion
CD154 is a known promising candidate molecule for the
immunotherapy of B-CLL because it increases the immunogenic-
ity of the tumor cells. In line, the ectopic expression of CD154 on
B-CLL cells was shown to induce the expression of important co-
stimulatory and adhesion molecules on the leukemic cells, turning
them into efficient stimulators of autologous T cells. In principle,
viral gene transfer of CD154 into B-CLL cells is a suitable
approach to induce immunological reactions both in vitro and in
vivo [14,26–29] but the low transduction efficiency and the
resulting high dose of viral vectors may induce severe side effects.
There also remain major concerns about the clinical use of viral
vectors.
Exosomes are cellular microvesicles, which have already
demonstrated their potential to induce specific immune responses.
The majority of permanent cell lines spontaneously release
exosomes into the supernatant, from where they can be easily
purified and concentrated [30]. Transfecting HEK293 cells with
expression plasmids coding for CD154 and gp350 resulted in the
secretion of modified exosomes carrying both proteins. Upon
interaction with their target B cells, an undetermined fraction of
exosomes is presumably engulfed and degraded in lysosomes in
such way that peptides of exosomal proteins are presented in
association with MHC class II molecules. Exosomes that are not
taken up by the target cells probably engage in protein-protein
contacts with cellular surface molecules and lead to receptor
activation and signaling. gp350 molecules on the surface of
exosomes probably target these vesicles exclusively to human B
cells which express relevant amounts of the receptor molecule for
gp350, CD21. Exosomal co-transfer of both gp350 and CD154
is thought to lead to efficient CD154/CD40 ligand/receptor
engagement on the B-cell surface activating the intrinsic CD40
signaling cascade.
Treatment of B-CLL cells with exosomes transferring functional
CD154 protein causes leukemia cells to become efficient APCs.
Activating the CD40 receptor leads to the induction of immune
accessory molecules, making these leukemic cells potent stimula-
tors of autologous T lymphocytes. Since almost all patients with
CLL have a high prevalence of EBV (94%) [31] and thus possess
EBV-specific memory cells with a high frequency of CD4+ gp350-
specific T cells [32], the incorporation of gp350 into exosomes has
a dual function: it confers B-cell tropism and serves as an
immunodominant viral CD4 antigen. The incorporation of a viral
protein as a tumor-specific antigen is straightforward, because the
cellular immune system of cancer patients is usually impaired but
virus-specific immune responses are detectable even in late-stage
patients and T lymphocytes specific for herpes viruses are often
present at high numbers [1,33]. Given the fact that the vast
majority of CLL patients are seropositive for EBV, gp350 and
Figure 3. CD154+/gp350+ exosomes reactivate gp350-specific
T cells. PBMCs from a patient diagnosed with B-CLL were stimulated
three times with CD154+/gp350+ exosomes and then used as effector
cells towards autologous calcein-labeled PBMCs loaded with the
exosomes indicated or not loaded with exosomes (w/o). PBMCs loaded
with CD154+/gp350+ exosomes were constantly better targets than
PBMCs loaded with CD154+ exosomes. Stimulated PBMCs were also
used as effector cells towards allogenic EBV+ LCL and EBV– B-blasts. The
fact that the LCL was efficiently lysed by stimulated PBMCs whereas the
B-blasts were not further indicates the reactivation of gp350-specific T-
cells. One out of three independent experiments are shown.
doi:10.1371/journal.pone.0025294.g003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e25294Figure 4. Stimulation with CD154+/gp350+ exosomes reactivates autologous T-cells from patients with B-CLL. Peripheral blood from a
patient with only 4% T-cell among his leukocytes at day 0 (left) were stimulated three times with different exosomes within a period of 31 days,
yielding a cell population that consisted to 58% of CD4+ and 31% of CD8+ T-cells (B). The stimulation of PBMCs with CD154+/gp350+ exosomes led
to a 23-fold and 15-fold increase in numbers of CD4+ and CD8+ T-cells, respectively, while (C) the total cell number slightly declined. No vital cells
were detectable after 31 days when PBMCs were stimulated with exosomes from parental 293 cells (293) or when cells were left untreated (w/o). One
representative experiment of five is shown. (D) Stimulation of B-CLL with CD154+/gp350+ exosomes let to the stimulation of tumor-specific T cells
that lysed allogenic, calcein-labeled B-blasts, loaded with A2-restricted peptides derived from known CLL-associated antigens (black columns) but not
unloaded B-blasts (grey columns). Peptides were derived from PU.1, mdm2 or ETV.5, which were all described as CLL-associated antigens. Blocking of
lysis upon addition of the MHC class I-blocking antibody W6/32 indicates MHC class I specificity and defines CD8+ T-cells as major effector cells. One
representative experiment of three is shown.
doi:10.1371/journal.pone.0025294.g004
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in B-CLL cells exploiting and redirecting the strong anti-viral
cellular immune responses to leukemic cells.
Based on these results, we propose here a new immunothera-
peutic approach for B-CLL, based on the simultaneous targeted
transfer of functional CD154 and the EBV protein gp350 onto
malignant cells using exosomes. gp350 is the major envelope
protein of EBV and confers viral B-cell tropism by interacting with
the complement receptor 2 (CD21), which is highly expressed on B
lymphocytes. Here, we generated modified exosomes produced in
293 cells. As a result of gp350 incorporation, these particles have a
profound B-cell tropism similar to wild-type EBV, so that gp350-
carrying vesicles specifically and efficiently bind to B cells. In
addition, gp350 serves as a viral neo-antigen in B-CLL cells. We
also found that CD154 on exosomes from HEK293 cells is
functionally active as demonstrated by the induction of immune
accessory molecules on B target cells probably through the CD40
pathway. Taken together, our experiments suggest that leukemia
cells treated with CD154+/gp350+ exosomes are efficiently
stimulated and subsequently killed by autologous B-CLL and
gp350-specific cytolytic T lymphocytes.
In summary, our results demonstrate that modified exosomes
carrying the EBV protein gp350 display a distinct tropism to
normal and leukemic B cells and efficiently transfer CD154 as a
functional protein onto these cells. Leukemic B cells treated with
these particles acquire an activated phenotype and become potent
stimulators of autologous T lymphocytes. Engineered exosomes
can be easily generated and can readily be scaled up for clinical
applications. In addition, they can be individually tailored to
express additional accessory molecules like OX40L or the Fas
ligand or alternative viral molecules to target other classes of cells
like macrophages and DCs. The generation of modified exosomes
is not limited to 293 cells, which we used in this proof-of-concept.
Instead, other cell lines that are approved for human therapy, such
as MRC-5 fibroblasts, should also be tested as an optional origin of
exosomes to facilitate transition into clinical trials. Modified
gp350-carrying exosomes can thus be regarded as powerful and
promising tools for various immunotherapeutic approaches.
Materials and Methods
Blood samples and cell preparation
Peripheral blood samples were obtained from patients with
diagnosis of B-CLL after informed consent approved by the
Institutional Ethics Committee. Normal blood samples were taken
from healthy volunteers. Mononuclear cells were isolated by
density gradient centrifugation on F/H. B cells were purified with
CD19-specific MACS beads (Miltenyi, Bergisch Gladbach,
Germany). Cells were cultured at 37uC in a 5% CO2 atmosphere
in standard medium with 10% fetal calf serum.
Isolation of exosomes
HEK293 is a human embryonic kidney cell line [34], which
spontaneously releases exosomes into the cell culture supernatant.
For the generation of modified exosomes, 293 cells were co-
transfected with expression plasmids for BLLF1 (gp350), CD154
and/or gfp. For the isolation of exosomes, 25 ml of conditioned
supernatants were collected three days later, sterile filtrated and
subjected to repeated centrifugations at increasing centrifugal
force (10 min at 300 x g, 10 min at 5000 x g in a Heraeus 3SR+-
centrifuge, followed by 2 h at 100.000 x g in a Beckman LE-80K
ultracentrifuge in a SW28 swing-out rotor. The pelleted particles
were washed, resuspended in 500 ml volume PBS containing
protease inhibitors (Complete Mini, Roche) and the protein
content was analyzed in a Lowry microassay using reagents
purchased from Bio-Rad (Munich, Germany). Exosomes were
further purified by flotation into a 5-30% iodixanol gradient
(OptiPrep
TM, Sigma Aldrich, Deisenhofen, Germany).
Binding assays and flow cytometry
B-CLL cells were cultivated with 100 mgo fe x o s o m e si naf i n a l
volume of 2 ml for two days. Induction of surface accessory molecules
was measured by flow cytometry using a FACS Calibur flow cytometer
(Becton Dickinson). For bead-coupling assays 5 ml of surfactant-free
sulfate/aldehyde latex beads were incubated with 10 mgo fe x o s o m e s
for 15 min at room temperature. Then 1 ml of PBS was added and the
beads were incubated for another 2 hours. The beads were washed
three times in PBS with 2% FCS and analyzed. Antibodies specific for
tsg101 (sc-978) and CD154 (sc-7964) were purchased from Santa Cruz
Biotechnology. E. Kremmer (Munich) provided the gp350-specific
antibody 72A1. Fluorochrome-labeled secondary antibodies were
obtained from Becton Dickinson (Heidelberg, Germany) or Immuno-
tools (Friesoyte, Germany).
Immunoblots
Vesicle preparations were spotted onto a PVDF membrane,
incubated with with specific primary antibodies and an HRP-
coupled secondary antibody and developed with the ECL system
(GE Healthcare). Ganglioside M1 was detected with colera toxin
(Sigma Aldrich).
T cell reactivation assays
In order to reactivate EBV-specific T-cells in B-CLL blood
samples, 3610
7 cells were cultivated with 100 mg of exosomes in a
final volume of 5 ml. Re-stimulations were performed on days 14
and 28 by adding 1610
7 lethally irradiated autologous PBMCs that
have been loaded with 100 mg exosomes for 5h. Fresh medium was
added once a week. After 31 days, cells were analyzed by flow
cytometry for lineage markers. Interferon-cELISA assays were
performed according to the manufacturers instructions (Mabtech,
Uppsala, Sweden). The gp350- and BNRF1-specific CD4+ HLA-
DR13-restricted T-cell clones used have been described elsewhere
[8,35]. All cells were tested in triplicates.
Cytotoxicity assays
Calcein release assays were performed as described previously [36].
Briefly, target cells were labeled with Calcein-AM (1% solution in
medium) for 30 min at 37uC. After intensive washing the cells were
either incubated with 10 mg of exosomes for 4 h or loaded with
CLL-specific, HLA-A2-restricted peptides (PU1.423: aa-sequence
VLFYLGQYI, mdm2.53: YLAPENGYL and ETV5.45: ELFQDL-
SQL) at 20 mg/ml for 1 h or left untreated. The cytotoxicity assays
were performed over a time period of 6 h, using an effector-target-
ratio of 40:1, and the calcein released into the supernatant was
quantified with excitation and emission wavelengths of 490 nm and
530 nm, respectively, in a plate-reader (Perkin Elmer, Waltham). All
experiments were performed at least three times.
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